SARS-CoV-2 variants are emerging with potential increased transmissibility highlighting the great unmet medical need for new therapies. Niclosamide is a potent anti-SARS-CoV-2 agent that has advanced in clinical development. We validate the potent antiviral efficacy of niclosamide in a SARS-CoV-2 human airway model. Furthermore, niclosamide remains its potency against the D614G, Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants. Our data further support the potent anti-SARS-CoV-2 properties of niclosamide and highlights its great potential as a therapeutic agent for COVID-19.
All Keywords
【초록키워드】 COVID-19, SARS-CoV-2, B.1.351, SARS-CoV-2 variant, Delta, B.1.617.2, anti-SARS-CoV-2, variants, Transmissibility, SARS-CoV-2 variants, B.1.1.7, therapeutic, D614G, Alpha, antiviral efficacy, Beta, therapeutic agent, Therapies, niclosamide, medical need, Support, clinical development, human airway, highlight, highlighting, 【제목키워드】 SARS-COV-2 infection, antiviral activity, delta variant, human airway, conserved,
【초록키워드】 COVID-19, SARS-CoV-2, B.1.351, SARS-CoV-2 variant, Delta, B.1.617.2, anti-SARS-CoV-2, variants, Transmissibility, SARS-CoV-2 variants, B.1.1.7, therapeutic, D614G, Alpha, antiviral efficacy, Beta, therapeutic agent, Therapies, niclosamide, medical need, Support, clinical development, human airway, highlight, highlighting, 【제목키워드】 SARS-COV-2 infection, antiviral activity, delta variant, human airway, conserved,
SARS-CoV-2 변종은 새로운 치료법에 대한 충족되지 않은 의학적 수요를 강조하면서 잠재적으로 증가된 전파 가능성과 함께 등장하고 있습니다. 니클로사미드는 임상 개발이 진행된 강력한 항 SARS-CoV-2 제제입니다. 우리는 SARS-CoV-2 인간 기도 모델에서 니클로사미드의 강력한 항바이러스 효능을 검증합니다. 또한, 니클로사미드는 D614G, 알파(B.1.1.7), 베타(B.1.351) 및 델타(B.1.617.2) 변이체에 대한 효능을 유지합니다. 우리의 데이터는 니클로사미드의 강력한 항 SARS-CoV-2 특성을 뒷받침하고 COVID-19 치료제로서의 큰 잠재력을 강조합니다.